Goodyear Tire & Rubber Co vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Goodyear Tire & Rubber Co trades at $4.78 (market cap $1.35B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is the larger of the two by market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| GT | NUVB | |
|---|---|---|
Market Cap | $1.35B | $1.71B |
Volume | 6,504,242 | 5,448,712 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $9.54 |
52-Week Low | $4.66 | $3.41 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $8.70B | $1.30B |
Signals from Pluang's Aura AI — not financial advice
GT trades at $4.75, down 1.93% in the last 24 hours, near its 52-week low. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $1.72B in 2025, with negative profit margins and declining revenue, though cash flow from operations improved to $796M. Recent news highlights restructuring efforts and a 'shrink-to-grow' strategy to boost margins.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include execution of the turnaround plan, competitive pressures, and macroeconomic headwinds. Institutional sentiment is mixed, with 34.6% of analysts rating it a buy.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →